NMRA — Neumora Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $344.42m
- $192.46m
- 10
- 15
- 89
- 31
Annual income statement for Neumora Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 99.2 | 237 | 136 | 252 | 263 |
| Operating Profit | -99.2 | -237 | -136 | -252 | -263 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -99.3 | -237 | -131 | -236 | -244 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -99.3 | -237 | -131 | -236 | -244 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -99.3 | -237 | -131 | -236 | -244 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -99.3 | -237 | -131 | -236 | -244 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.168 | -0.529 | -0.776 | -1.08 | -1.53 |
| Dividends per Share |